We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Inhibition Control of Children and Adolescents With ADHD

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: September 3, 2012
Last Update Posted: September 3, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
National Taiwan University Hospital

The objectives of this study are to investigate:

  1. the effect of methylphenidate on attention;
  2. the relations between methylphenidate and inhibition control and working memory;
  3. the relations between inhibition control and verbal attention and working memory;
  4. the effect of methylphenidate on the changes of neuropsychological functioning and blood pressure.

Attention Deficit Hyperactivity Disorder

Study Type: Observational
Official Title: Inhibition Control of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Resource links provided by NLM:

Further study details as provided by National Taiwan University Hospital:

Enrollment: 60
Study Start Date: November 2011
Study Completion Date: March 2012
Detailed Description:
Attention deficit hyperactivity disorder (ADHD), characterized by inattention, hyperactivity and impulsivity, is an early onset, highly heritable, clinically heterogeneous, long-term impairing disorder with tremendous impact on individuals, families, and societies. It affects 5-10% of school-aged children worldwide (7.5% in Taiwan). Methylphenidate, a stimulant, is effective in treating these patients. Studies in Taiwan show no effect of methylphenidate on blood pressure. There are evidences show that the change of blood pressure was associated with inhibition of impulsive behaviors. Stop Signal Task(SST) is used to assess the improve of inhibition control after methylphenidate response. By using repeated outcome measurements, we anticipate that this study will evaluate the improvement of neuropsychological performances after medication and determinie the association between medication response and neuropsychological functions and vital signs in a Taiwanese sample.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   10 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
We will recruit 60 children and adolescents, aged 10 to 18, who are diagnosed with ADHD at the Department of Psychiatry, National Taiwan University Hospital.

Inclusion Criteria:

The inclusion criteria for the subjects are (1)that subjects have a clinical diagnosis of ADHD defined by the DSM-IV which was made by a full-time board-certificated child psychiatrist; (2)their ages range from 10 to 18 when we conduct the study; (3)their IQ greater than 80; and (4)they are under treatment of methylphenidate.

Exclusion Criteria:

The subjects will be excluded from the study if they currently meet criteria or have a history of the following condition as defined by DSM-IV: Schizophrenia, Schizoaffective Disorder, Organic Psychosis, or Pervasive Developmental Disorder.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01677819

National Taiwan Univeristy Hospital
Taipei, Taiwan
Sponsors and Collaborators
National Taiwan University Hospital
Principal Investigator: Susan Shur-Fen Gau, MD, PhD National Taiwan University Hospital & College of Medicine
  More Information

Responsible Party: National Taiwan University Hospital, Susan Shur-Fen Gau
ClinicalTrials.gov Identifier: NCT01677819     History of Changes
Other Study ID Numbers: 201109027RD
First Submitted: August 30, 2012
First Posted: September 3, 2012
Last Update Posted: September 3, 2012
Last Verified: August 2012

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms